Introduction
According to De Caterina, 1 the interaction between diet and genotype is bidirectional. On the one hand, the environment (nutrients) can affect gene expression (nutrigenomics). On the other hand, genes can moderate the effect of environmental factors, such as dietary intake, on disease development (nutrigenetics). Recent research has also indicated that both under-and overnutrition can contribute to heritable changes in the genome, without changes in deoxyribonucleic acid (DNA) sequence (epigenetics). These changes are the result of molecular modifications of DNA through methylation, as well as histone (DNA packaging protein) modification. 2, 3 Epigenetic effects are specifically prominent during pregnancy, including the periconceptional period, but also during neonatal development, puberty, and in the aged. 3 Genes that may specifically hold epigenetic memories of early life experiences include those directly associated with energy intake, storage and use. 3 It is possible that epigenetics may influence obesity phenotype indicators. The findings by Lawlor et al, 4 that maternal overnutrition may contribute to the transfer of obesity from one generation to the next via epigenetic effects, supports this possibility.
To date, most research on nutrigenetics has focused on singlenucleotide polymorphisms (SNPs). 5 SNPs are point mutations in genes that account for most genetic variance involving differences in DNA sequence. 6 Results emanating from this work support the notion that interactions between genes, diet, other lifestyle factors, disease, and time (life cycle span), contribute to the risk of most polygenic nutrition-related diseases. [7] [8] [9] [10] When considering the association between genotype and disease risk, it is important to bear in mind that individual susceptibility SNPs, involved in the development of polygenic diseases, typically make a relatively small contribution to the overall homeostasis, function and health of an individual. 11 It follows that the presence of susceptibility SNPs does not necessarily result in the development of the disease in question. It must further be considered that a particular SNP could have both susceptibility and protective effects. A well-known example that illustrates this concept involves the C677T polymorphism in the methylenetetrahydrofolate reductase (MTHFR)
gene. MTHFR plays a role in the remethylation of homocysteine to methionine. 12 The TT variant has been shown to result in increased homocysteine levels, increasing the risk for neural tube defects and
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To ensure evidence-based practice, the research design and methodology applied in the investigation of relevant associations, and confirmation of causality, should be appropriate and rigorous. 10 
Research design and methods for nutrigenetics research
The first line of evidence in nutrigenetics involves the establishment of associations between a particular genotype and one, or more, phenotype indicators of a particular disease ( Appropriate sample size to ensure representativeness.
Use of appropriate genetic markers, robust (valid) lifestyle (diet) and phenotype indicators.
Poor study design.
Small samples.
Sampling bias.
Almost total lack of assessment of lifestyle (diet) indicators.
Step 2
Confirmation of causality or hypothesis testing (interventions)
Prospective interventions to confirm causality.
Appropriate sample size for sufficient statistical power.
Use of appropriate genetic markers, robust (valid) lifestyle (diet) and phenotype indicators or outcomes.
Prospective sampling of genotype groups.
Equal number of subjects in the variant and wild type homozygote and heterozygote groups.
Rotation of interventions across all genotype groups, and across race groups as relevant, which requires consecutive weigh loss periods and return to baseline weight, to "test" each "type of diet" in each of the three genotypes Confirmation of compliance.
Small samples
Sampling bias, retrospective genotyping.
Almost total lack of assessment and control for lifestyle (diet) indicators, as well as compliance thereto.
Short duration of weight loss interventions (< 6 months).
Lack of rotation across genotype groups, as it is extremely challenging, if not impossible.
Steps 1 and 2
Use of appropriate statistical analyses or tests or modelling.
Validation of statistical models.
Consideration of multiple-test burden that may result in false positives.
Control for confounders or interactions, including gene-gene interactions, age, gender, race, disease, medication use, and geographical variation.
Consolidation of outcomes in meta-analytic approaches.
Consideration of systems genetics for integrative studies of gene-gene lifestyle (diet)-disease-time interactions.
2012;25(1) S Afr J Clin Nutr personalised to the individual's genotype to ensure optimal prevention or treatment outcomes. With this in mind, the clinical application of such screening tests needs to be considered. Should screening only apply to individuals with a family history of a particular disease, or those with diagnosed risk indicators, or who present with the disease? Should healthy individuals with no diagnosable risks of a disease, or family history thereof, be screened? The latter may result in intervention in asymptomatic individuals, for a disease that may never develop, 7, 21 as the predictive value of susceptibility SNPs is low. 8 For application in evidence-based practice, susceptibility testing should meet the following criteria:
• The clinical validity of the test must have been clearly established, 22 following the steps outlined in Table I. • Evidence-based, acceptable and accessible interventions must be available to those who test positive for a particular susceptibility genotype.
21
• Health professionals, including dietitians, who are competent in interpreting the outcomes of such tests, and in counselling clients accordingly, must be in place.
11,22
Whether or not these criteria are met by commercialised susceptibility gene screening, has been questioned in different forums.
Evans et al 24 contend that available interventions are often untested.
They also mention that recommendations are very likely to be based on presumed benefit, rather than on outcomes of well-designed Genotype-based personalised nutrition for the prevention and treatment of obesity Obesity develops when energy intake exceeds energy expenditure.
According to Stipanuk, 23 the interaction between genotype and environmental factors possibly explains the majority of variance in body weight: "Obesity is most likely to occur when a genetically susceptible individual encounters an environment that is conducive to obesity".
Identification of susceptibility genes for obesity initially followed the candidate gene approach (Table II) Research on the effect of the interaction between genotype for these genes and diet (and other lifestyle) indicators on obesity indicators is scarce, while well-designed interventions to confirm causality could not be traced. The complexity of translation of nutrigenetics-related information into evidence-based dietary guidelines can be illustrated using the ADRB3 Trp64Arg polymorphism that has been included in some commercial gene screens for personalisation of weight-loss recommendations, as an example. Meta-analysis of association studies has shown that Arg64-allele carriers have a 0.24 kg/m 2 higher BMI, compared to the Trp64Trp homozygotes in Asians. 25 This association was not found in Caucasians. 25, 26 One of the very few studies on the effect of the interaction between the presence of the ADRB3 Trp64Arg polymorphism, and diet indicators on BMI (obesity phenotype indicator), was conducted by Miyaki et al 27 in Japanese subjects. These researchers concluded that only Arg 64 allele carriers with the highest energy intakes exhibited an increased obesity risk. A number of researchers have also investigated the effect of the ADRB3 Trp64Arg polymorphism on the response to a standard conservative diet (thus not personalised according to genotype, and is not a confirmation of causality) in Caucasians (sample sizes 25-85) [27] [28] [29] [30] and Asians (sample sizes 24-88). [29] [30] [31] Asian, but not Caucasian, Arg64 allele carriers, were found to lose less weight and fat, especially visceral fat, when exposed to a conservative weight loss programme. Translation of these findings into genotype-based personalised weight-loss guidelines could involve recommendations for very low energy intakes and high levels of physical activity for Asian Arg64 allele carriers. Whether such genotype-based guidelines are truly effective should be tested in well-designed intervention studies, once causality has been established. No such research could be traced for the ADRB3 Trp64Arg polymorphism, indicating that screening for this SNP for personalisation of weight-loss diets would be premature at this point in time.
According to Vimaleswaran and Loos, 21 genome-wide association (GWA) scans are rapidly contributing to more insight in the field of obesity genetics. Through GWA scans, the FTO gene (fat-mass and obesity-associated gene) has been confirmed as the first gene that is unquestionably associated with common obesity. Ongoing research to identify the functional role of the FTO gene in relevant metabolic pathways, indicates that it is most probably implicated in controlling energy homeostasis and eating behaviour. [34] [35] [36] [37] [38] [39] Certain SNPs in this gene have also been associated with increases in BMI, as well as decreased lipolytic activity, independent of BMI. 35, 40 However, investigation of the effect of the interaction between FTO genotypes and diet indicators on obesity indicators, as well as confirmation of causality, is only beginning to emerge.
The process of identifying further loci (specific locations of genes on chromosomes) associated with obesity is ongoing. Speliotes et al 41 reported 18 new loci that are associated with BMI at genome-wide significance level (p-value < 5.0 x 10 -8 ), bringing the total number of such loci to 32. These findings were based on a GWA meta-analysis, including approximately 249 796 individuals of European ancestry. Speliotes et al 41 predict that 284 further common loci with effects on BMI, similar to the confirmed loci, may be identified in future. It is important to note that the combined effect of the SNPs at the 32 confirmed loci on the variance in BMI is a modest 1.45%, bearing in mind that the estimated heritability of obesity is estimated to be 40-70%. 40 Furthermore, resequencing and fine mapping of most of the identified loci still need to be carried out to identify causal SNPs. Clear connections to the biology of weight regulation are also not known for most of the loci. Speliotes et al 41 emphasise that Table III : Ethics-related points for consideration in the implementation of genotype-based personalised nutrition
Key aspect Points to consider
Robust causality and intervention effectiveness (utility) evidence
Limited availability of robust evidence, both for causality and effectiveness of genotype-based nutrition. This may result in nonevidence-based recommendations and practice.
Analytical validity of genotyping Occurrence of laboratory errors in gene analyses. This may be especially true for uncontrolled online and home test kits.
Informed consent Informed consent should cover the small risk contribution of single-nucleotide polymorphisms to polygenic diseases, available interventions, deoxyribonucleic acid banking or storage, and disclosure of information (intended and unintended) to relatives. The testing of children for adult onset polygenic diseases (with parents' consent) is a concern.
Test recommendation, interpretation and subsequent counselling
The availability of health professionals, including dieticians, who are competent in recommending, interpreting the outcomes of evidence-based tests for susceptibility single nucleotide polymorphisms, and appropriate counselling of clients.
Privacy of information and discrimination
Protection of privacy rights, i.e. right not to disclose test results to employers, medical and other insurance providers. This is complicated by a lack of understanding of the nature of polygenic conditions, as well as the associated low-risk contribution of single-nucleotide polymorphisms by employers, insurance companies and society, which may result in various forms of discrimination.
Advertising and media coverage of tests and public expectation
Advertisements and media coverage of commercial tests contribute to popular understanding of genotype-based personalised nutrition. They may not necessarily reflect evidence-based information, and may result in consumers being misled or even harmed. Public expectation is not necessarily motivated by the discovery of hidden abnormalities, but rather by the need for reassurance (that members of the public have no unusual problems).
Psychological impact A positive test may result in anxiety about increased disease risk, while the risk for development of the disease may be low. This might result in a fatalistic approach to personal health management, and might divert attention away from modifiable lifestyle risks. A negative test may cause relief, resulting in a perception of "no genetic risk", and a maverick approach ("No need to heed the guidelines for a healthy lifestyle") .
Equity
Availability to all sectors of the population.
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Ethical issues related to genotype-based personalised nutrition
The increasing application of nutrigenetics research outcomes in genotype-based personalised nutrition has resulted in a discourse on potential ethical issues (Table III) on various platforms. According to Levesque et al, 42 ethical developments in this field have been outpaced by nutrigenetics bioscience. Marketing of genotype-based personalised nutrition, especially online, and often without the input of appropriately qualified health professionals, now seems to be common practice. The potential nonadherence to relevant ethical principles, as mentioned in Table III , and lack of regulation in this regard, are serious concerns. It may be argued, as Ioannidis 17 points out in an editorial on "personalised genetic prediction", that "we adopted nearly all pregenomic-era tests without waiting for large, well designed, pragmatic randomised trials". However, Ioannidis goes on to say that "we should not use past mistakes as an excuse for present inaction". This view supports that of Caulfield, 43 who, after their investigation of marketing dilemmas associated with current nutrigenetic services, concluded that it is important for more research to focus on the ethical, legal, and social aspects of such services, to ensure evidence-based, cost-effective practice in the prevention, or treatment of, common nutrition-related diseases.
Conclusion
The escalation of identification of new loci associated with obesity indicators seems daunting. It is clear that translation of these insights into evidence-based guidelines for the prevention and treatment of obesity depends on the identification of causal SNPs in loci associated with BMI, establishment of the functional roles of identified SNPs in obesity-related metabolic pathways, investigation of the effect of the interaction between genotypes for specific SNPs and lifestyle (dietary intake and physical activity) indicators on obesity indicators, and confirmation of causality. All these outcomes should be integrated, using, for example, systems genetics to account for interactions between genes, diet, other lifestyle factors, disease, and time (life cycle span).
Conclusions formulated by various researchers on the translation of nutrigenetics research into personalised nutrition, including obesity prevention and management, indicate that generally, scientists hold the opinion that more research is necessary before evidence-based practice in this area can be guaranteed (Table IV) .
Ultimately, when behaviour change for the improvement of health outcomes is considered, whether genotype-based or not, some practice-related issues will remain. The most pertinent of these are that people will continue to develop diseases, while non-compliance to prevention or disease management guidelines, disparities in access to health services, and the potential for unproven and fraudulent medical practices and malpractice, will remain as challenges. 2 In an editorial in Nature outlook, Grayson 51 summarises the situation as follows: "Some people predict an age of diets customised to individual energy needs and disease susceptibility. But no matter how good the science is, or how well we are able to exploit food as an agent of healthfulness, we will still be eating for pleasure for some time yet". Meanwhile, while evidence seems to be accumulating for possible personalisation of nutrition based on genotype, Simopoulos 52 recommends the dissemination of dietary guidelines that are in line with the South African food based dietary guidelines at population level, to prevent disease and improve nutrition-related health outcomes in general. At present, the evidence base for genotype-specific dietary advice is limited. This may change, but it seems too early to estimate how autonomy and benefits should be balanced against each other in such a possible future."
Rimbach and Minihane
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"Although the evidence base in nutrigenetics is growing, with sufficient data to provide a 'proof of principle' of its potential utility in public health, this area currently suffers from a lack of consistent findings."
Bouchard and Agurs-Collins 20 "Finally, a major challenge will remain as to how to translate advances in our understanding of gene-behaviour interaction effects for public health consumption, when promoting weight gain prevention, and for clinical practice, in the context of treatment of obesity, and its associated morbidities."
Kussmann et al 3 "Genome-wide associations have identified a number of (candidate) risk loci for the development or (early) onset of certain diseases, including common and complex ones. However, the power of these risk loci to predict health trajectories, has, so far, been small, even if several loci have meanwhile been replicated, and taken together in a combined score."
De Caterina 1
